RxDoctor Payments Data

Mark Tackett, MD

Family Medicine · Powderly, KYNPI 1144281791

Payments from drug & device makers

$1,880in general payments, 2019–2025

Across 148 payments — averaging $12.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$301
  • Novo Nordisk$276
  • AstraZeneca$202
  • Lilly USA, LLC$169
  • Boehringer Ingelheim$145
  • GSK$137
  • plus $649 from 11 others

What the payments were for

  • Food & beverage$1,86099%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,880 in reported general payments places this provider in the 65th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$257,560
Medicare patients
1,055
Services billed
8,950

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban338$192,530
JardianceEmpagliflozin240$139,431
JanuviaSitagliptin Phosphate132$75,357
OzempicSemaglutide73$71,778
MounjaroTirzepatide30$52,211
TrulicityDulaglutide46$50,783
XareltoRivaroxaban62$42,484
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog60$42,361
FarxigaDapagliflozin Propanediol80$29,420
LinzessLinaclotide28$25,837
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog108$23,616
Tresiba Flextouch U-100Insulin Degludec36$22,056
RybelsusSemaglutide22$19,757
ProzacFluoxetine Hcl15$18,916
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$18,087

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Lyrica$48$204,736352 claims
Boehringer IngelheimJardiance, Synjardy Xr$145$156,327252 claims
Lilly USA, LLCMounjaro, Trulicity$169$102,99476 claims
Novo NordiskOzempic, Rybelsus$276$91,53695 claims
MerckJanuvia$12$75,357132 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$202$50,319131 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta$137$46,37887 claims
Johnson & JohnsonXarelto$43$42,48462 claims
AbbVieLinzess$110$25,83728 claims
Astellas Pharma US IncMyrbetriq$125$15,09034 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Powderly

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →